Zydus receives approval for Imatinib Mesylate tablets

Zydus Cadila announced that the company has received a final approval from US Food & Drug Administration (USFDA) to market Imatinib Mesylate tablets, 100 mg and 400 mg.

Imatinib Mesylate tablets, 100 mg and 400 mg, is a medication used for treating certain types of leukemia (blood cancer), bone marrow disorders, skin cancer and tumors of stomach and digestive system. In a press release, the company stated that the drug will be manufactured at the group’s manufacturing facility located at SEZ in Ahmedabad.

Recently, the company announced that it has initiated an accelerated research programme with multiple teams in India and Europe for developing a vaccine for the novel Coronavirus, 2019-nCoV (COVID-19) based on two approaches: With development of a DNA vaccine against the major viral membrane protein, responsible for the cell entry of COVID-19 and with development of a live attenuated recombinant measles virus vectored vaccine against COVID-19.

Zydus Cadila is an innovative, global pharmaceutical company engaged in the discovery, development, manufacturing and marketing of a broad range of healthcare therapies. The group employs nearly 25,000 people worldwide and is dedicated in creating healthier communities globally. Zydus aspires to be a research-based pharmaceutical company by 2020. The group currently has 285 approvals and has so far, filed over 386 ANDAs since the commencement of the filing process in FY 2003-2004.

On Thursday, the stock of the company closed at Rs 350.70, up by 0.21 per cent or Rs 0.75 per share. The 52-week high is Rs 378 and 52-week low is Rs 206.45 on BSE.